BofA raised the firm’s price target on Quest Diagnostics (DGX) to $245 from $225 and keeps a Buy rating on the shares after Q1 results came in well ahead of guidance and the Street, with volume growth “the clear highlight.” Quest continues to execute well, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $230 from $225 at Barclays
- Quest Diagnostics Lifts Outlook On Strong Earnings Call
- Quest Diagnostics price target raised to $225 from $210 at Evercore ISI
- Quest Diagnostics price target raised to $225 from $220 at Jefferies
- Midday Fly By: Apple names new CEO, Amazon ups investment in Anthropic